Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina Aims For All-Inclusive Cancer Screen Via New Start-Up

This article was originally published in The Gray Sheet

Executive Summary

Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.

Advertisement

Related Content

Big Pharma Helps Pour $900m Into Grail
VC Deals Analysis: 2016 Bucks The Trend As Investment Dollars Dip
Device/Diagnostics Quarterly Deal Statistics, Q1 2016
Start-Up Quarterly Statistics, Q1 2016
FDA Approves First Next-Generation DNA Sequencing Platforms
NEWS IN BRIEF

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel